Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (91-100 of 232) with videos related to

Pageof 24
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2000
Ly-49P activates NK-mediated lysis by recognizing H-2DdE T Silver, D E Gong, C S Chang, et al.
Leukemia|July 1, 1991
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemiaA Grossman, R T Silver, T P Szatroswki, et al.
Canadian Journal of Genetics and Cytology. Journal Canadien De Genetique Et De Cytologie|December 1, 1986
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemiaR S Verma, J Rodriguez, A Babu, et al.
Journal of Cancer Research and Clinical Oncology|September 10, 1999
Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancerG T Budd, J Atiba, R T Silver, et al.
Molecular Cancer Research : MCR|January 31, 2003
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cellsAnnabel Strife, David Wisniewski, Chongyuan Liu, et al.
American Journal of Human Genetics|November 1, 1989
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemiaA Grossman, R T Silver, Z Arlin, et al.
Cancer Chemotherapy Reports|May 11, 1975
Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208)R A Kyle, B R Seligman, H J Wallace, et al.
Medical and Pediatric Oncology|January 1, 1984
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patientsM S Brower, M Coleman, M W Pasmantier, et al.
Orthodontics & Craniofacial Research|October 27, 2018
A modified Steiner's analysis that does not require radiographic exposure of the cranial baseStephanie C Finn, Mathew T Silver, Benjamin Canary, et al.
Blood|September 25, 1998
A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemiaI Buño, W A Wyatt, A R Zinsmeister, et al.
Pageof 24

Showing results (91-100 of 232) with videos related to

Sort By:
Pageof 24
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2000
Ly-49P activates NK-mediated lysis by recognizing H-2DdE T Silver, D E Gong, C S Chang, et al.
Leukemia|July 1, 1991
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemiaA Grossman, R T Silver, T P Szatroswki, et al.
Canadian Journal of Genetics and Cytology. Journal Canadien De Genetique Et De Cytologie|December 1, 1986
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemiaR S Verma, J Rodriguez, A Babu, et al.
Journal of Cancer Research and Clinical Oncology|September 10, 1999
Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancerG T Budd, J Atiba, R T Silver, et al.
Molecular Cancer Research : MCR|January 31, 2003
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cellsAnnabel Strife, David Wisniewski, Chongyuan Liu, et al.
American Journal of Human Genetics|November 1, 1989
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemiaA Grossman, R T Silver, Z Arlin, et al.
Cancer Chemotherapy Reports|May 11, 1975
Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208)R A Kyle, B R Seligman, H J Wallace, et al.
Medical and Pediatric Oncology|January 1, 1984
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patientsM S Brower, M Coleman, M W Pasmantier, et al.
Orthodontics & Craniofacial Research|October 27, 2018
A modified Steiner's analysis that does not require radiographic exposure of the cranial baseStephanie C Finn, Mathew T Silver, Benjamin Canary, et al.
Blood|September 25, 1998
A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemiaI Buño, W A Wyatt, A R Zinsmeister, et al.
Pageof 24